EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

被引：3
|
作者：
Le, Xiuning [1 ]
Nadler, Eric [2 ]
Costa, Daniel B. [3 ]
Heymach, John Victor [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Baylor Univ, Med Ctr, Dallas, TX USA
[3] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA USA
来源：
TARGETED ONCOLOGY | 2023年 / 18卷 / 06期
关键词：
AFATINIB; OSIMERTINIB; NSCLC;
D O I：
10.1007/s11523-023-00994-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[media not available: see fulltext]
引用
收藏
页码：807 / 817
页数：11
相关论文
共 50 条
  • [1] EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
    Xiuning Le
    Eric Nadler
    Daniel B. Costa
    John Victor Heymach
    Targeted Oncology, 2023, 18 : 807 - 817
  • [2] Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
    Xiuning Le
    Eric Nadler
    Daniel B. Costa
    John Victor Heymach
    Targeted Oncology, 2024, 19 : 125 - 125
  • [3] EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast (vol 18, pg 807, 2023)
    Le, Xiuning
    Nadler, Eric
    Costa, Daniel B.
    Heymach, John Victor
    TARGETED ONCOLOGY, 2024, 19 (01) : 125 - 125
  • [4] Treatment outcomes with tyrosine kinase inhibitors in patients with uncommon EGFR mutations in non-small cell lung cancer
    Hunter, S.
    Nickless, G.
    Ghosh, S.
    Lal, R.
    Merrick, S. A.
    Montes, A.
    Smith, D.
    Spicer, J.
    Karapanagiotou, E.
    LUNG CANCER, 2017, 103 : S34 - S35
  • [5] Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib
    Masood, Ashiq
    Kancha, Rama Krishna
    Subramanian, Janakiraman
    SEMINARS IN ONCOLOGY, 2019, 46 (03) : 271 - 283
  • [6] Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors
    Heigener, David F.
    Schumann, Christian
    Sebastian, Martin
    Sadjadian, Parvis
    Stehle, Ingo
    Maerten, Angela
    Lueers, Anne
    Griesinger, Frank
    Scheffler, Matthias
    ONCOLOGIST, 2015, 20 (10): : 1167 - 1174
  • [7] Impact of EGFR-Tyrosine Kinase Inhibitors for Postoperative Recurrent Non-Small Cell Lung Cancer Harboring EGFR Mutations
    Igawa, S.
    Sato, Y.
    Kusuhara, S.
    Harada, S.
    Shirasawa, M.
    Kurahayashi, S.
    Okuma, Y.
    Sugimoto, A.
    Sugita, K.
    Nakahara, Y.
    Otani, S.
    Fukui, T.
    Yokoba, M.
    Mitsufuji, H.
    Kubota, M.
    Katagiri, M.
    Sasaki, J.
    Masuda, N.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2126 - S2127
  • [8] Tyrosine Kinase Inhibitors Could Be Effective Against Non-small Cell Lung Cancer Brain Metastases Harboring Uncommon EGFR Mutations
    Ma, Chunhua
    Zhang, Juncheng
    Tang, Dongjiang
    Ye, Xin
    Li, Jing
    Mu, Ning
    Li, Zhi
    Liu, Renzhong
    Xiang, Liang
    Huang, Chuoji
    Jiang, Rong
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [9] Efficacy of EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Patients Harboring Different Types of EGFR Mutations:A Retrospective Analysis
    刘华丽
    韩光
    彭敏
    翁一鸣
    袁静萍
    杨桂芳
    于金明
    宋启斌
    Current Medical Science, 2017, 37 (06) : 864 - 872
  • [10] Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis
    Hua-li Liu
    Guang Han
    Min Peng
    Yi-ming Weng
    Jing-ping Yuan
    Gui-fang Yang
    Jin-ming Yu
    Qi-bin Song
    Current Medical Science, 2017, 37 : 864 - 872
12345